Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atibuclimab (IC14) for Acute Decompensated Heart Failure
NCT06556810Phase 2Active, not recruiting
- Sponsor
- Implicit Bioscience
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atibuclimab in heart failure (HF), sponsored by Implicit Bioscience. Primary endpoints: Safety of IC14 treatment and Anti-Drug Antibodies. Started Oct 2024; status: active, not recruiting.
02
Drugs
atibuclimab
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06556810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556810.